JP2024512255A5 - - Google Patents
Info
- Publication number
- JP2024512255A5 JP2024512255A5 JP2023550240A JP2023550240A JP2024512255A5 JP 2024512255 A5 JP2024512255 A5 JP 2024512255A5 JP 2023550240 A JP2023550240 A JP 2023550240A JP 2023550240 A JP2023550240 A JP 2023550240A JP 2024512255 A5 JP2024512255 A5 JP 2024512255A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- chain variable
- variable region
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163152100P | 2021-02-22 | 2021-02-22 | |
| US63/152,100 | 2021-02-22 | ||
| PCT/US2022/017222 WO2022178382A1 (en) | 2021-02-22 | 2022-02-22 | Method for diagnosing and treating partial lipodystrophy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024512255A JP2024512255A (ja) | 2024-03-19 |
| JP2024512255A5 true JP2024512255A5 (enExample) | 2025-02-13 |
Family
ID=80683255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023550240A Pending JP2024512255A (ja) | 2021-02-22 | 2022-02-22 | 部分性脂肪萎縮症を診断および処置するための方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240153638A1 (enExample) |
| EP (1) | EP4294257B1 (enExample) |
| JP (1) | JP2024512255A (enExample) |
| DK (1) | DK4294257T3 (enExample) |
| ES (1) | ES3055018T3 (enExample) |
| FI (1) | FI4294257T3 (enExample) |
| HR (1) | HRP20251599T1 (enExample) |
| LT (1) | LT4294257T (enExample) |
| PL (1) | PL4294257T3 (enExample) |
| PT (1) | PT4294257T (enExample) |
| RS (1) | RS67523B1 (enExample) |
| SI (1) | SI4294257T1 (enExample) |
| SM (1) | SMT202500444T1 (enExample) |
| WO (1) | WO2022178382A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020150473A2 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
| BR112021013924A2 (pt) | 2019-01-18 | 2021-09-21 | Astrazeneca Ab | Inibidores de pcsk9 e métodos de uso do mesmo |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI824372B (zh) | 2015-10-12 | 2023-12-01 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| SMT202500283T1 (it) * | 2018-04-06 | 2025-09-12 | Regeneron Pharma | Un anticorpo agonista del recettore della leptina da utilizzare per aumentare la massa ossea in un soggetto affetto da disfunzione metabolica o ipoleptinemia |
-
2022
- 2022-02-22 JP JP2023550240A patent/JP2024512255A/ja active Pending
- 2022-02-22 EP EP22708698.0A patent/EP4294257B1/en active Active
- 2022-02-22 WO PCT/US2022/017222 patent/WO2022178382A1/en not_active Ceased
- 2022-02-22 LT LTEPPCT/US2022/017222T patent/LT4294257T/lt unknown
- 2022-02-22 SI SI202230205T patent/SI4294257T1/sl unknown
- 2022-02-22 FI FIEP22708698.0T patent/FI4294257T3/fi active
- 2022-02-22 US US18/547,150 patent/US20240153638A1/en active Pending
- 2022-02-22 PL PL22708698.0T patent/PL4294257T3/pl unknown
- 2022-02-22 RS RS20251266A patent/RS67523B1/sr unknown
- 2022-02-22 HR HRP20251599TT patent/HRP20251599T1/hr unknown
- 2022-02-22 ES ES22708698T patent/ES3055018T3/es active Active
- 2022-02-22 PT PT227086980T patent/PT4294257T/pt unknown
- 2022-02-22 SM SM20250444T patent/SMT202500444T1/it unknown
- 2022-02-22 DK DK22708698.0T patent/DK4294257T3/da active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN118488853A (zh) | 组合疗法 | |
| JP2022534020A5 (enExample) | ||
| JP2023548858A5 (enExample) | ||
| RU2006120950A (ru) | Антитело к cd40: препарат и способы | |
| JP2021526534A5 (enExample) | ||
| JP2024524159A (ja) | 代謝障害の治療における使用のためのｇｌｐ－１経路活性化剤と組み合わせたミオスタチン経路阻害剤 | |
| WO2002096461A1 (en) | Use of anti-tnf antibodies as drugs in treating septic disorders of anemic patients | |
| JP7663559B2 (ja) | Ａｃｔｒｉｉ受容体拮抗薬を含む肝疾患または肝臓障害の治療 | |
| JP2021532057A5 (enExample) | ||
| JP2020500852A5 (enExample) | ||
| JP2021525718A5 (enExample) | ||
| WO2019160057A1 (ja) | 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 | |
| FI4294257T3 (fi) | Menetelmä osittaisen lipodystrofian diagnosoimiseksi ja hoitamiseksi | |
| TW202430247A (zh) | 肌肉生長抑制素活化之選擇性及強效抑制劑 | |
| CN105251004A (zh) | 在诊断和治疗类风湿性关节炎中使用的包含抗-cd6单克隆抗体的药物组合物 | |
| JP2026048712A (ja) | 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン | |
| JP2005515214A5 (enExample) | ||
| JP2021532176A5 (enExample) | ||
| Muso et al. | Intravenous immunoglobulin (IVIg) therapy in MPO-ANCA related polyangiitis with rapidly progressive glomerulonephritis in Japan | |
| US20200231666A1 (en) | Treatment paradigm | |
| JP2024531314A (ja) | 小児ｍｓを治療するためのオファツムマブ | |
| JP2022529929A5 (enExample) | ||
| EP2545936A2 (en) | Methods, compositions, and kits for treating Shiga toxin associated conditions | |
| KR20160141727A (ko) | Cd19-항체 약물 컨쥬게이트의 최적의 주입 | |
| KR20200083996A (ko) | 인터류킨-17(il-17)을 사용하여 건병증을 치료하는 방법 |